Literature DB >> 25131981

HDL and cardiovascular disease.

Daniel J Rader1, G Kees Hovingh2.   

Abstract

The cholesterol contained within HDL is inversely associated with risk of coronary heart disease and is a key component of predicting cardiovascular risk. However, despite its properties consistent with atheroprotection, the causal relation between HDL and atherosclerosis is uncertain. Human genetics and failed clinical trials have created scepticism about the HDL hypothesis. Nevertheless, drugs that raise HDL-C concentrations, cholesteryl ester transfer protein inhibitors, are in late-stage clinical development, and other approaches that promote HDL function, including reverse cholesterol transport, are in early-stage clinical development. The final chapters regarding the effect of HDL-targeted therapeutic interventions on coronary heart disease events remain to be written.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131981     DOI: 10.1016/S0140-6736(14)61217-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  195 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

Review 2.  Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins.

Authors:  Abhishek K Singh; Binod Aryal; Xinbo Zhang; Yuhua Fan; Nathan L Price; Yajaira Suárez; Carlos Fernández-Hernando
Journal:  Semin Cell Dev Biol       Date:  2017-12-06       Impact factor: 7.727

3.  Revisiting "Good" and "Bad" Cholesterol. The Battle over Flow through Arteries Now Shifts to Flow through Airways.

Authors:  Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

4.  Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.

Authors:  Hagai Tavori; Yan Ru Su; Patricia G Yancey; Ilaria Giunzioni; Ashley J Wilhelm; John L Blakemore; Manal Zabalawi; MacRae F Linton; Mary G Sorci-Thomas; Sergio Fazio
Journal:  J Lipid Res       Date:  2015-01-15       Impact factor: 5.922

5.  [HDL and atherosclerotic cardiovascular diseases].

Authors:  E Windler; S Nitschmann
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

6.  A thrombotic storm.

Authors:  Sarah Damanti; Andrea Artoni; Tiziano Lucchi; Pier Mannuccio Mannucci; Daniela Mari; Luigi Bergamaschini
Journal:  Intern Emerg Med       Date:  2016-11-23       Impact factor: 3.397

7.  Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.

Authors:  Margaret E Gatti-Mays; David Venzon; Claudia E Galbo; Andrea Singer; James Reynolds; Erini Makariou; Bhaskar Kallakury; Brandy M Heckman-Stoddard; Larissa Korde; Claudine Isaacs; Robert Warren; Ann Gallagher; Jennifer Eng-Wong
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-12

Review 8.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

Review 9.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

Review 10.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.